2021-2031 Cancer Diagnostics Market Report


New York, June 04, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Cancer Diagnostics Market Report 2021-2031” – https://www.reportlinker.com/p06089506/?utm_source=GNW

Cancer Diagnostics Market – Our New Study Reveals Trends, R&D Advances, and Forecast Revenues Over Next Decade

Growing demand for non-invasive cancer diagnosis

Major investments have been made by companies in the cancer diagnostics sector in recent years to develop new tests to capitalize on untapped market opportunities. For example, VolitionRx Limited released its Nu.Q colorectal cancer triage test in Europe. Likewise, OncoCyte Corporation, developer of the new DetermaIO, a biomarker of the neoadjuvant response to checkpoint inhibitors in triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), is expected to be launched in the States. -Unis by 2H2021. All of these factors are expected to provide lucrative growth opportunities for players in the cancer diagnostics market during the forecast period.

North America Currently Dominates the Global Cancer Diagnostics Market

Based on regions, the global cancer diagnostics market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. According to the analysis, cancer diagnostics in North America accounted for the majority of the market share and are expected to experience significant growth during the forecast period of 2021 to 2031. The growth is attributed to the increasing burden of cancer which is influenced by many factors, such as aging. populations and changing lifestyles. Patients are encouraged to use health facilities by improving remuneration. Various cancer prevention programs are organized by government agencies (such as the Colorectal Cancer Control Program) to increase cancer screening in men and women aged 50 and over.

How do leading players strengthen their position in the global business?

Our report reveals the technologies and companies that hold the greatest potential. In particular, explore and analyze the activities of these companies. See where the expected gains will be. View the outlook assessment of established competitors, emerging companies and new market entrants. Our work explains this potential and helps you stay ahead of the curve. Gain an in-depth understanding of the competitive landscape with profiles of leading companies by examining their positioning, capabilities, product portfolios, R&D activities, services, priorities, strategies, M&A activities and their outlook.

Find out how to stay ahead

Our 590+ page report provides over 600 tables and charts / graphs. Read on to discover the most lucrative areas in the industry and future market prospects. Our new study enables you to assess expected sales in the overall global market and regionally. View financial results, trends, opportunities and revenue forecasts. There remain many opportunities in this growing cancer diagnostics market. See how to exploit the opportunities.

Cancer diagnostics market segmentation

Type of test
. Tumor biomarker tests
. PSA tests
. CTC tests
. AFP tests
. CA-19 tests
. HER2 tests
. BRCA tests
. ALK tests
. CEA tests
. EGFR mutation tests
. KRAS mutation tests
. Other
. Imagery
. Ultrasound
. Mammography
. PET Scan
. SPECT and others
. Biopsy
. Needle biopsy
. Endoscopic biopsy
. Bone marrow biopsy
. Other
. Liquid biopsy
. Immunohistochemistry
. In situ hybridization

Type of cancer
. Breast cancer
. Lung cancer
. Colorectal cancer
. Melanoma
. Leukemia
. Prostate cancer
. Ovarian cancer
. Stomach cancer
. Liver cancer
. Other

Final user
. Associated hospital laboratories
. Independent diagnostic laboratories
. Diagnostic imaging centers
. Cancer research institutes
. Other end users

By region
. North America
. we
. Canada
. Europe
. Germany
. UK
. France
. Italy
. Spain
. Russia
. Poland
. The rest of europe
. Japan
. Asia-Pacific excluding Japan
. China
. Australia
. India
. Singapore
. South Korea
. Thailand
. Rest of Asia-Pacific
. Latin America
. Brazil
. Mexico
. Argentina
. Rest of Latin America
. Middle East and Africa
. South Africa
. Rest of Middle East and Africa

COVID-19 impact recovery scenarios

This report includes baseline forecast as well as different rebound scenarios to help analyze the global cancer diagnostics market regardless of how COVID-19 is affecting the economy.

2031 forecast and other analysis reveal business outlook
. In addition to the revenue forecast to 2031, our new research provides you with recent results, growth rates and market share.
. You will find original analyzes, with perspectives and commercial developments.
. Discover qualitative analyzes (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and business developments.

Leading countries and market growth potential

The overall global cancer diagnostics market revenue will exceed $ xx billion by 2021, by our calculations. We forecast strong revenue growth through 2031. Our work identifies organizations that hold the greatest potential. Learn about their capabilities, progress and business prospects, helping you stay ahead of the curve.

How the Cancer Diagnostics Market Report Helps You

In summary, our report of over 590 pages provides you with the following knowledge:
. Revenue forecast till 2031 for Cancer Diagnostics Market, with forecast for production process, application, product, and material each forecast at global and regional level – learn the outlook for the industry , finding the most lucrative places for investment and income
. Revenue forecast to 2031 for 5 regional markets and 21 key national markets – See forecast for Cancer Diagnostics market in North America, Europe, Asia-Pacific, Latin America, Middle East and South Africa. The market is also expected in the United States, Canada, Germany, United Kingdom, France, Italy, Russia, Japan, China, India, Australia, Brazil, Mexico, the CCG and South Africa, among other significant economies.
. Outlook for established companies and those looking to enter the market, including company profiles of 16 of the major companies involved in the cancer diagnostics market. Some of the companies described in this report are Abbott, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips NV, Toshiba Medical Systems Corporation , Agilent Technologies, Inc., Quest Diagnostics, Genomic Health (Exact Sciences Corporation), BioMark Diagnostics Inc., Hologic, Inc., QIAGEN and BD among other leading players.

Find quantitative and qualitative analyzes with independent predictions. Receive information that only our report contains, stay informed with this valuable business intelligence.

With our new report title, you’re less likely to fall behind in your knowledge or miss out on opportunities. See how our work could benefit your research, analysis and decisions. This study is aimed at all those who require business analyzes for the cancer diagnostics market and leading companies. There you will find data, trends and forecasts.

Who should read this report?
. Senior executives
. Business development managers
. Marketing Directors
. Advisers
. CEOs
. Governments, agencies and organizations actively working or interested in the cancer diagnostics industry will also find significant value in our research.

Read the full report: https://www.reportlinker.com/p06089506/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


Leave A Reply

Your email address will not be published.